Program
VH5356136
A development code. Also written as “VH5356136 Formulation 1” and “VH5356136 Formulation 2”.
Its studies are mostly in HIV Infections, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 11 open or running | phase 1since Sep 10, 2026 | Sep 10, 2026 | May 9, 2029phase 1 · NCT07822477 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 10, 2026First study: phase 1 study in HIV InfectionsFirst studyNCT07822477 · 160 planned
Ahead
- May 9, 2029Primary completion: phase 1 study in HIV InfectionsNCT07822477
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07822477HIV Infections | 1 | Not yet recruiting | May 9, 2029 | 160 |
How it is read
Names in the registry
- “VH5356136 Formulation 1”, 1 entry
- “VH5356136 Formulation 2”, 1 entry
Codes read as this program: VH5356136.
Conditions, from the studies’ own filings
- HIV Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.